News tagged with ipilimumab

Researchers test safety of Nivolumab in kidney cancer

Researchers at Dartmouth-Hitchcock Norris Cotton Cancer Center will present a poster on a phase I clinical trial of Nivolumab, a PD-1 receptor blocking antibody, being used in combination with other drugs in patients with ...

Jun 03, 2013
popularity 0 comments 0

New therapy is tolerable in lung cancer

A promising new therapy for the most common form of lung cancer appears to produce largely manageable side effects, and an ongoing clinical trial is determining whether the compound treats tumors more effectively than what's ...

May 31, 2013
popularity 0 comments 0

ASCO: combo antibody therapy effective for melanoma

(HealthDay)—Concurrent use of two immune checkpoint antibodies—ipilimumab and nivolumab—may be effective for the treatment of advanced melanoma, according to a proof-of-principal study presented in ...

May 17, 2013
popularity 0 comments 0

Bright future ahead for antibody cancer therapy

Antibodies, once touted as the "magic bullets" of cancer care, are now fulfilling that promise and more advances are on the way, say cancer researchers at the Georgetown Lombardi Comprehensive Cancer Center

Mar 15, 2012
popularity 0 comments 0

US approves new drug against skin cancer

A breakthrough drug that could extend survival in some patients with advanced skin cancer was approved on Wednesday by US regulators, offering the first new treatment for melanoma in 13 years.

Aug 17, 2011
popularity 0 comments 0

Ipilimumab

Ipilimumab (also known as MDX-010 or MDX-101), marketed as Yervoy, is a drug used for the treatment of melanoma, a type of skin cancer. It is a U.S. Food and Drug Administration (FDA) approved human monoclonal antibody developed by Bristol-Myers Squibb, and works by activating the immune system.

Additionally, ipilimumab is undergoing clinical trials for the treatment of non-small cell lung carcinoma (NSCLC), small cell lung cancer (SCLC) and metastatic hormone-refractory prostate cancer.

This text uses material from Wikipedia licensed under CC BY-SA